Literature DB >> 30012605

Delineating the role of cooperativity in the design of potent PROTACs for BTK.

Adelajda Zorba1,2, Chuong Nguyen2, Yingrong Xu2, Jeremy Starr2, Kris Borzilleri2, James Smith2, Hongyao Zhu3, Kathleen A Farley2, WeiDong Ding2, James Schiemer2, Xidong Feng2, Jeanne S Chang2, Daniel P Uccello2, Jennifer A Young2, Carmen N Garcia-Irrizary2, Lara Czabaniuk2, Brandon Schuff2, Robert Oliver2, Justin Montgomery2, Matthew M Hayward2, Jotham Coe2, Jinshan Chen2, Mark Niosi4, Suman Luthra5, Jaymin C Shah5, Ayman El-Kattan4, Xiayang Qiu2, Graham M West2, Mark C Noe2, Veerabahu Shanmugasundaram2, Adam M Gilbert2, Matthew F Brown2, Matthew F Calabrese6.   

Abstract

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that simultaneously bind to a target protein and an E3 ligase, thereby leading to ubiquitination and subsequent degradation of the target. They present an exciting opportunity to modulate proteins in a manner independent of enzymatic or signaling activity. As such, they have recently emerged as an attractive mechanism to explore previously "undruggable" targets. Despite this interest, fundamental questions remain regarding the parameters most critical for achieving potency and selectivity. Here we employ a series of biochemical and cellular techniques to investigate requirements for efficient knockdown of Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase essential for B cell maturation. Members of an 11-compound PROTAC library were investigated for their ability to form binary and ternary complexes with BTK and cereblon (CRBN, an E3 ligase component). Results were extended to measure effects on BTK-CRBN cooperative interactions as well as in vitro and in vivo BTK degradation. Our data show that alleviation of steric clashes between BTK and CRBN by modulating PROTAC linker length within this chemical series allows potent BTK degradation in the absence of thermodynamic cooperativity.

Entities:  

Keywords:  BTK; PROTAC; catalytic; proteasome; targeted protein degradation

Mesh:

Substances:

Year:  2018        PMID: 30012605      PMCID: PMC6077745          DOI: 10.1073/pnas.1803662115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation.

Authors:  Eric S Fischer; Andrea Scrima; Kerstin Böhm; Syota Matsumoto; Gondichatnahalli M Lingaraju; Mahamadou Faty; Takeshi Yasuda; Simone Cavadini; Mitsuo Wakasugi; Fumio Hanaoka; Shigenori Iwai; Heinz Gut; Kaoru Sugasawa; Nicolas H Thomä
Journal:  Cell       Date:  2011-11-23       Impact factor: 41.582

2.  NuRD-ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination.

Authors:  Dimitri Conomos; Roger R Reddel; Hilda A Pickett
Journal:  Nat Struct Mol Biol       Date:  2014-08-24       Impact factor: 15.369

3.  A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation.

Authors:  Joseph J Higgins; Joanna Pucilowska; Roni Q Lombardi; John P Rooney
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

4.  A comprehensive mathematical model for three-body binding equilibria.

Authors:  Eugene F Douglass; Chad J Miller; Gerson Sparer; Harold Shapiro; David A Spiegel
Journal:  J Am Chem Soc       Date:  2013-04-16       Impact factor: 15.419

5.  Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.

Authors:  Afua A Akuffo; Aileen Y Alontaga; Rainer Metcalf; Matthew S Beatty; Andreas Becker; Jessica M McDaniel; Rebecca S Hesterberg; William E Goodheart; Steven Gunawan; Muhammad Ayaz; Yan Yang; Md Rezaul Karim; Morgan E Orobello; Kenyon Daniel; Wayne Guida; Jeffrey A Yoder; Anjali M Rajadhyaksha; Ernst Schönbrunn; Harshani R Lawrence; Nicholas J Lawrence; Pearlie K Epling-Burnette
Journal:  J Biol Chem       Date:  2018-02-15       Impact factor: 5.157

Review 6.  Ibrutinib in B-cell Lymphomas.

Authors:  Kami Maddocks; Kristie A Blum
Journal:  Curr Treat Options Oncol       Date:  2014-06

7.  Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.

Authors:  Andrew L Rankin; Nilufer Seth; Sean Keegan; Tatyana Andreyeva; Tim A Cook; Jason Edmonds; Nagappan Mathialagan; Micah J Benson; Jameel Syed; Yutian Zhan; Stephen E Benoit; Joy S Miyashiro; Nancy Wood; Shashi Mohan; Elena Peeva; Shashi K Ramaiah; Dean Messing; Bruce L Homer; Kyri Dunussi-Joannopoulos; Cheryl L Nickerson-Nutter; Mark E Schnute; John Douhan
Journal:  J Immunol       Date:  2013-09-25       Impact factor: 5.422

8.  Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase.

Authors:  Geng Wu; Guozhou Xu; Brenda A Schulman; Philip D Jeffrey; J Wade Harper; Nikola P Pavletich
Journal:  Mol Cell       Date:  2003-06       Impact factor: 17.970

9.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Authors:  Jennifer A Woyach; Amy S Ruppert; Daphne Guinn; Amy Lehman; James S Blachly; Arletta Lozanski; Nyla A Heerema; Weiqiang Zhao; Joshua Coleman; Daniel Jones; Lynne Abruzzo; Amber Gordon; Rose Mantel; Lisa L Smith; Samantha McWhorter; Melanie Davis; Tzyy-Jye Doong; Fan Ny; Margaret Lucas; Weihong Chase; Jeffrey A Jones; Joseph M Flynn; Kami Maddocks; Kerry Rogers; Samantha Jaglowski; Leslie A Andritsos; Farrukh T Awan; Kristie A Blum; Michael R Grever; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 50.717

View more
  86 in total

Review 1.  Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective.

Authors:  Xinrui Yang; He Yin; Richard D Kim; Jason B Fleming; Hao Xie
Journal:  Target Oncol       Date:  2020-12-28       Impact factor: 4.493

2.  Selective degradation of CDK6 by a palbociclib based PROTAC.

Authors:  Sandeep Rana; Mourad Bendjennat; Smit Kour; Hannah M King; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2019-03-26       Impact factor: 2.823

3.  A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.

Authors:  Fu Gui; Jie Jiang; Zhixiang He; Li Li; Yunzhan Li; Zhou Deng; Yue Lu; Xinrui Wu; Guyue Chen; Jingyi Su; Siyang Song; Yue-Ming Zhang; Cai-Hong Yun; Xin Huang; Ellen Weisberg; Jianming Zhang; Xianming Deng
Journal:  Br J Pharmacol       Date:  2019-12-09       Impact factor: 8.739

Review 4.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

5.  PROTAC Technology: Opportunities and Challenges.

Authors:  Hongying Gao; Xiuyun Sun; Yu Rao
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345

6.  A kinetic proofreading model for bispecific protein degraders.

Authors:  Derek W Bartlett; Adam M Gilbert
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-22       Impact factor: 2.745

Review 7.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 8.  Proteolysis-targeting chimeras in drug development: A safety perspective.

Authors:  Kevin Moreau; Muireann Coen; Andrew X Zhang; Fiona Pachl; M Paola Castaldi; Goran Dahl; Helen Boyd; Clay Scott; Pete Newham
Journal:  Br J Pharmacol       Date:  2020-02-25       Impact factor: 8.739

9.  Hydrogen-Deuterium Exchange and Hydroxyl Radical Footprinting for Mapping Hydrophobic Interactions of Human Bromodomain with a Small Molecule Inhibitor.

Authors:  Ke Sherry Li; Elizabeth T Schaper Bergman; Brett R Beno; Richard Y-C Huang; Ekaterina Deyanova; Guodong Chen; Michael L Gross
Journal:  J Am Soc Mass Spectrom       Date:  2019-11-12       Impact factor: 3.109

10.  Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.

Authors:  Dennis Dobrovolsky; Eric S Wang; Sara Morrow; Catharine Leahy; Tyler Faust; Radosław P Nowak; Katherine A Donovan; Guang Yang; Zhengnian Li; Eric S Fischer; Steven P Treon; David M Weinstock; Nathanael S Gray
Journal:  Blood       Date:  2018-12-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.